Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Ähnliche Einträge

• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  von: Faisal I. Almohaileb, et al.
  Veröffentlicht: (2025)
• Obstructive sleep apnea is associated with impaired insulin clearance and hepatic insulin sensitivity in paediatric obesity
  von: Giuseppina Rosaria Umano, et al.
  Veröffentlicht: (2025)
• Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes
  von: Ebaa Al‐Ozairi, et al.
  Veröffentlicht: (2024)
• Obstructive sleep apnea is associated with greater MASH and significant fibrosis severity in patients with obesity: A prospective clinicopathological study
  von: Jia Feng, et al.
  Veröffentlicht: (2026)
• Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
  von: Carel W. le Roux, et al.
  Veröffentlicht: (2024)